High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone non-Hodgkin' s lymphoma

( views:370, downloads:0 )
Author:
MENG Xiang-rui(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Sino-US Center of Lymphoma and Leukemia, Tianjin 300060, China)
WANG Hua-qing(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Sino-US Center of Lymphoma and Leukemia, Tianjin 300060, China)
CUI Xiu-zhen(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Sino-US Center of Lymphoma and Leukemia, Tianjin 300060, China)
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
Volume 21, Issue 10, 2012
DOI:
10.3760/cma.j.issn.1009-9921.2012.10.006
Key Word:
Hematopoietic stem cell transplantation;Lymphoma,B-cell,marginal zone;Relapsed;Refractory

Abstract: Objective To evaluate the role of high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone lymphomas. Methods The transplant database was reviewed retrospectively from Tianjin Medical University Cancer Hospital identified 12 patients who underwent high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation. Results Among the twelve patients who underwent autologous hematopoietic stem cell transplantation, the median duration of progression-free survival (PFS) was 104 months and the median duration overall survival (OS) was 117 months; 6 patients were still alive with disease-free. Conclusion High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation is feasible to patients with relapsed/refractory marginal zone lymphomas, particularly to those insensitive to rituximabincluded combined chemotherapy.

  • [1]Swerdiow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues.4th ed. Lyon: IARC Press,2008:185-188.
  • [2]Li L, Bierman P, Vose J, et al. High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk,2011,11:253-256.
  • [3]达伟,张伟京,苏航,等.利妥昔单抗联合化疗治疗CD+20的B细胞型非霍奇金淋巴瘤27例.白血病·淋巴瘤,2006,15:371-372.
  • [4]沈元元,王会平,张翠,等.利妥昔单抗治疗老年人脾边缘区淋巴瘤二例并文献复习.白血病·淋巴瘤,2011,20:247-249.
  • [5]Witzig TE,Geyer SM,Kurtin PJ,et al.Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin's lymphoma: a phase Ⅱ trial in the North Centerl Cancer Treatment Group. Leuk Lymphoma,2008,49:1074-1080.
  • [6]Tsang RW,Gospodarowicz MK,Pintilie M,et al.Localized mucosaassociated lymphoma tissue lymphoma treated with radiation therapy has excellent chinical outcome.J Clin Oncol,2003,21:4157-4164.
  • [7]Montalban C,Sant6n A,Redondo C,et al.Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with Helicobacter pylori eradication.Lack of association with translocation t (11;18):a 10-year updated follow-up a prospective study.Ann Oncol,2005,16:1539-1544.
  • [8]Raderer M,Streubel B,W(o)hrer S,et al.High relapse rate in patients with MALT lymphoma warrants life long follow-up. Clin Cancer Res,2005,11:3349-3352.
  • [9]Raderer M, W(o)hrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience.J Clin Oncol,2006,24:3136-3141.
  • [10]Hitchcock S,Ng AK,Fisher DC,Silver B,et al.Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.Int J Radiat Oncol Biol Phys,2002,52:1058-1066.
  • [11]Arcaini L,Pauli M,Burcheri S,et al.Primary nodal marginal zone B-cell lymphoma:clinical features and prognostic assessment of a rare disease.Br J Haematal,2007,136:301-304.
  • [12]Leahy MF,Seymour JF,Hicks R J,et al.Multicenter phase Ⅱ clinical iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.J Clin Oncol,2006,24:4418-4425.
  • [13]Conconi A,Martinelli G,Thieblemont C,et al.Clinical activity of rituximab in extranodal marginal zone lymphoma of MALT type.Blood,2003,102:2741-2745.
  • [14]J(a)ger G,Neumeister P,Brezinschek R,et al.Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissuetype with cladribine:a phase Ⅱ study.J Clin Oncol,2002,20:3872-3877.
  • [15]Martinelli G,Laszlo D,Ferreri AJ,et al.Clinical Activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter Pvlori therapy.J Clin Oncol,2005,23:1979-1983.
  • [16]Oh SY, Kim WS, Kim JS, et al. Stage Ⅳ marginal zone B-cell lymphoma-prognostic factors and the role of rituximab:Consortium for Improving Survival of Lymphoma (CISL) study.Cancer Sci,2010,101:2443-2447.
  • [17]Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma.Semin Hematol,2010,47:143-147.
  • [18]Raderer M, W(o)hrer S,Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/ mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology,2006,70:411-417.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn